Yann Le Cam
Overview
Explore the profile of Yann Le Cam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Whiting A, Rath A, Anido R, Ardigo D, Baynam G, et al.
Orphanet J Rare Dis
. 2024 Sep;
19(1):334.
PMID: 39261914
Improving health and social equity for persons living with a rare disease (PLWRD) is increasingly recognized as a global policy priority. However, there is currently no international alignment on how...
2.
Faye F, Crocione C, Anido de Pena R, Bellagambi S, Escati Penaloza L, Hunter A, et al.
Eur J Hum Genet
. 2024 May;
32(9):1116-1126.
PMID: 38755315
Timely diagnosis is one of the most serious challenges faced by people living with a rare disease (PLWRD), and this study estimates that in Europe, the average total diagnosis time...
3.
Bhatia S, Le Cam Y, Carrion J, Diamond L, Fennessy P, Gassman S, et al.
Mol Ther Methods Clin Dev
. 2024 Mar;
32(2):101220.
PMID: 38516694
No abstract available.
4.
Cavaller-Bellaubi M, Hughes-Wilson W, Kubinova S, van de Casteele M, Van Lente E, Degortes E, et al.
Orphanet J Rare Dis
. 2023 Jun;
18(1):144.
PMID: 37308991
Background: The Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA) was established in 2013 with the intention of developing a coordinated mechanism between volunteering EU stakeholders and developers of...
5.
Sikonja J, Groselj U, Scarpa M, la Marca G, Cheillan D, Kolker S, et al.
Int J Neonatal Screen
. 2022 Jun;
8(2).
PMID: 35645285
Although individual rare disorders are uncommon, it is estimated that, together, 6000+ known rare diseases affect more than 30 million people in Europe, and present a substantial public health burden....
6.
Aartsma-Rus A, Dooms M, Le Cam Y
Front Pharmacol
. 2022 Jan;
12:744532.
PMID: 34975469
Today policy makers face the challenge to devise a policy framework that improves orphan medicinal product (OMP) development by creating incentives to deliver treatments where there are none and to...
7.
Bolz-Johnson M, Kenny T, Le Cam Y, Hernando I
J Community Genet
. 2021 Apr;
12(2):241-246.
PMID: 33884523
Healthcare is continually evolving to meet the changing needs of twenty-first century populations whilst striving to keeping pace with medical and technological advancements. Patients and clinicians remain the constants in...
8.
Rath A, Lambert D, Olry A, Rodwell C, Le Cam Y
Eur J Hum Genet
. 2020 Dec;
29(6):1034-1035.
PMID: 33262444
No abstract available.
9.
Wakap S, Lambert D, Olry A, Rodwell C, Gueydan C, Lanneau V, et al.
Eur J Hum Genet
. 2019 Sep;
28(2):165-173.
PMID: 31527858
Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy. We used the publicly available epidemiological data in the...
10.
Eichler H, Barker R, Bedlington N, Bouvy J, Broekmans A, Bucsics A, et al.
Nat Rev Drug Discov
. 2018 Jul;
17(12):845-846.
PMID: 29977052
No abstract available.